QUIA PHARMA AB (FRA:99B0) Notes Receivable: €0.00 Mil (As of Jun. 2025)


What is QUIA PHARMA AB Notes Receivable?

QUIA PHARMA AB FRA:99B0 Notes Receivable is €0.00 Mil as of Jun. 2025. The stock has 3 warning signs investors should review.

QUIA PHARMA AB's Notes Receivable for the quarter that ended in Jun. 2025 was €0.00 Mil.

QUIA PHARMA AB Notes Receivable Historical Data

* Premium members only.

The historical data trend for QUIA PHARMA AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

QUIA PHARMA AB Notes Receivable Chart

QUIA PHARMA AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

QUIA PHARMA AB Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

QUIA PHARMA AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
QUIA PHARMA AB (FRA:99B0) has a Notes Receivable of €0.00 Mil as of Jun. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on QUIA PHARMA AB and its competitors.
Is QUIA PHARMA AB's Notes Receivable too high?
QUIA PHARMA AB's current Notes Receivable is €0.00 Mil.
How does QUIA PHARMA AB's Notes Receivable compare to VRTX and REGN?
QUIA PHARMA AB's Notes Receivable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on QUIA PHARMA AB and its competitors. QUIA PHARMA AB's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is QUIA PHARMA AB stock overvalued right now?
QUIA PHARMA AB (FRA:99B0) has a current Notes Receivable of €0.00 Mil. The current Notes Receivable is €0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For QUIA PHARMA AB (FRA:99B0), the current Notes Receivable is €0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

QUIA PHARMA AB Business Description

Address Virdings Alle 32 B, Uppsala, SWE, 754 50
QUIA PHARMA AB is a development company for pharmaceuticals based on a patented drug delivery platform, Uni-Qleaver. The company develops improved and patentable forms of drugs under development or already approved by pharmaceutical authorities. These refined and enhanced forms of medicine are based on the Company's exceptional and patented technology platform. In addition to this, the Company offers multinational sales of omega-3, astaxin and collagen through Amazon.